Neuronetics Inc (STIM) Expected to Announce Quarterly Sales of $14.69 Million

Wall Street analysts expect Neuronetics Inc (NASDAQ:STIM) to announce $14.69 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Neuronetics’ earnings, with estimates ranging from $14.68 million to $14.71 million. The firm is expected to issue its next quarterly earnings report on Tuesday, February 5th.

On average, analysts expect that Neuronetics will report full year sales of $51.83 million for the current fiscal year, with estimates ranging from $51.82 million to $51.85 million. For the next fiscal year, analysts forecast that the firm will post sales of $62.74 million, with estimates ranging from $62.30 million to $63.17 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Neuronetics.

Neuronetics (NASDAQ:STIM) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.11. The company had revenue of $13.74 million for the quarter, compared to analyst estimates of $12.68 million.

A number of equities research analysts recently commented on the company. BTIG Research reaffirmed a “buy” rating and set a $33.00 price objective on shares of Neuronetics in a research note on Thursday, August 16th. JMP Securities lifted their target price on Neuronetics from $36.00 to $40.00 and gave the stock an “outperform” rating in a report on Wednesday, August 15th. Canaccord Genuity lifted their target price on Neuronetics from $33.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday, August 15th. Piper Jaffray Companies assumed coverage on Neuronetics in a report on Monday, July 23rd. They set an “overweight” rating on the stock. Finally, William Blair assumed coverage on Neuronetics in a report on Monday, July 23rd. They set an “outperform” rating on the stock. Six analysts have rated the stock with a buy rating, Neuronetics presently has a consensus rating of “Buy” and a consensus price target of $34.50.

Shares of Neuronetics stock traded up $0.55 during trading on Monday, reaching $18.10. 257,527 shares of the company were exchanged, compared to its average volume of 90,530. The company has a quick ratio of 7.46, a current ratio of 7.63 and a debt-to-equity ratio of 0.33. Neuronetics has a twelve month low of $16.38 and a twelve month high of $39.39.

A number of hedge funds have recently bought and sold shares of the business. Alpine Woods Capital Investors LLC lifted its holdings in Neuronetics by 40.0% during the third quarter. Alpine Woods Capital Investors LLC now owns 14,000 shares of the company’s stock worth $449,000 after acquiring an additional 4,000 shares in the last quarter. American International Group Inc. bought a new position in Neuronetics during the third quarter worth about $136,000. Victory Capital Management Inc. bought a new position in Neuronetics during the second quarter worth about $133,000. Pier Capital LLC bought a new position in Neuronetics during the second quarter worth about $186,000. Finally, Teachers Advisors LLC bought a new position in Neuronetics during the third quarter worth about $267,000. Hedge funds and other institutional investors own 60.78% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood.

Recommended Story: Earnings Per Share (EPS)

Get a free copy of the Zacks research report on Neuronetics (STIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply